Retinal Vein Occlusion News and Research

RSS
Central retinal vein occlusion (CRVO) is the most common disease of the retinal vessels. It refers to a blockage of the vein draining the retinal tissue at the back of the eye. Occurring mostly in the elderly or middle-aged, it causes a subacute loss of vision.
Regeneron reports total revenues of $123.0M for fourth quarter 2011

Regeneron reports total revenues of $123.0M for fourth quarter 2011

ForSight VISION4 to receive first milestone payment for Lucentis drug delivery device

ForSight VISION4 to receive first milestone payment for Lucentis drug delivery device

Clearside Biomedical receives $4M venture capital investment

Clearside Biomedical receives $4M venture capital investment

IRIDEX announces data from MicroPulse laser therapy study on DME

IRIDEX announces data from MicroPulse laser therapy study on DME

Lucentis receives Health Canada approval for treatment of retinal vein occlusion

Lucentis receives Health Canada approval for treatment of retinal vein occlusion

Bayer Yakuhin seeks marketing authorization in Japan for EYLEA for treatment of wet AMD

Bayer Yakuhin seeks marketing authorization in Japan for EYLEA for treatment of wet AMD

PDL revises revenue guidance for second quarter 2011 to $122M

PDL revises revenue guidance for second quarter 2011 to $122M

Bayer HealthCare seeks EU marketing authorization of VEGF Trap-Eye for treatment of wet AMD

Bayer HealthCare seeks EU marketing authorization of VEGF Trap-Eye for treatment of wet AMD

Bayer, Regeneron initiate two VEGF Trap-Eye Phase 3 trials in Diabetic Macular Edema

Bayer, Regeneron initiate two VEGF Trap-Eye Phase 3 trials in Diabetic Macular Edema

Phase III RISE study of Lucentis for DME meets primary endpoint

Phase III RISE study of Lucentis for DME meets primary endpoint

Positive top-line results from VEGF Trap-Eye Phase 3 studies in macular edema due to CRVO

Positive top-line results from VEGF Trap-Eye Phase 3 studies in macular edema due to CRVO

Allergan third quarter diluted loss per share increases to $2.21

Allergan third quarter diluted loss per share increases to $2.21

FDA approves OZURDEX implant for uveitis treatment

FDA approves OZURDEX implant for uveitis treatment

PDL BioPharma reports revenue guidance of $86 million for 2010 third quarter

PDL BioPharma reports revenue guidance of $86 million for 2010 third quarter

Allergan second-quarter diluted EPS increases to $0.78

Allergan second-quarter diluted EPS increases to $0.78

Regeneron second-quarter total revenues increase to $115.9 million

Regeneron second-quarter total revenues increase to $115.9 million

Genentech's Lucentis for treatment of macular edema following RVO receives FDA approval

Genentech's Lucentis for treatment of macular edema following RVO receives FDA approval

Winners of BioMed Central Annual Research Awards announced

Winners of BioMed Central Annual Research Awards announced

Report shows increasing rates of AMD among Asians

Report shows increasing rates of AMD among Asians

REGN reports net loss of $30.5M for first-quarter 2010

REGN reports net loss of $30.5M for first-quarter 2010